Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new antiinflammatory agent (EGIS-5645) without gastrointestinal side-effect.

G Gigler1, E Kiszelly, P Tömpe

  • 1EGIS Pharmaceuticals, Budapest, Hungary.

Agents and Actions. Supplements
|January 1, 1991
PubMed
Summary

EGIS-5645 is a potent antipyretic, analgesic, and anti-inflammatory agent with no gastro-ulcerogenic effects. It effectively treats inflammation without inhibiting prostaglandin biosynthesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>In vivo</i> estimation of chicken breast and thigh muscle weights using multi-atlas-based elastic registration on computed tomography images.

British poultry science·2025
Same author

Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.

Pulmonary circulation·2024
Same author

Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy.

Journal of autoimmunity·2024
Same author

TONI - One for all? Participatory development of a transtheoretic and transdiagnostic online intervention for blended care.

Internet interventions·2024
Same author

Airway guidelines: Addressing the gaps.

Revista espanola de anestesiologia y reanimacion·2024
Same author

Multiparametric imaging guided HDR interventional radiotherapy (brachytherapy) boost in localized prostate cancer: a multidisciplinary experience.

European review for medical and pharmacological sciences·2023

Area of Science:

  • Pharmacology
  • Drug Discovery

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) often cause gastrointestinal side effects.
  • There is a need for effective anti-inflammatory agents with improved safety profiles.

Purpose of the Study:

  • To evaluate the efficacy and safety of the novel compound EGIS-5645.
  • To assess its anti-inflammatory, analgesic, and antipyretic properties.
  • To investigate its gastro-ulcerogenic potential and mechanism of action.

Main Methods:

  • Carrageenan-induced paw edema model in rats.
  • Adjuvant-induced arthritis model in rats.
  • Assessment of gastro-ulcerogenic effects.
  • Inhibition assays for prostaglandin biosynthesis and soybean lipoxygenase.

Related Experiment Videos

Main Results:

  • EGIS-5645 demonstrated significant anti-inflammatory activity in both carrageenan-induced edema and adjuvant arthritis models.
  • The compound exhibited potent antipyretic and analgesic properties.
  • EGIS-5645 showed minimal to no gastro-ulcerogenic effects.
  • No significant inhibition of prostaglandin biosynthesis or soybean lipoxygenase activity was observed.

Conclusions:

  • EGIS-5645 is a promising anti-inflammatory agent with a favorable safety profile.
  • Its anti-inflammatory effects may be mediated through mechanisms independent of prostaglandin synthesis inhibition.
  • Further research into EGIS-5645's unique mechanism of action is warranted.